Hester Biosciences plans capacity expansion to manufacture Goat Pox Vaccine; stock skyrockets ~10%

26 Sep 2022 , 09:38 AM

Hester Biosciences Limited informed that it identified the early warning signals of a probable outbreak and began producing vaccine supplies in preparation for an increase in demand. As a consequence, Hester has been able to satisfy the whole demand for the supply of Goat Pox vaccination in the country.

There has been no short supply of the vaccine in any state in India, said the company.

Hester is planning to expand its capacity in preparation for the production of increased quantities of the Goat Pox vaccine. Further, to assure the continued production and delivery of all other vaccinations against poultry, sheep, goat, and cattle.

This capacity increase is scheduled to be finished in January 2023.

Furthermore, ICAR-IVRI has collaborated to develop a vaccine for Lumpy Skin Disease. Hester will acquire the technology and produce and sell the Lumpy Skin Disease Vaccine as soon as the technology becomes available.

At around 9.42 AM, Hester Biosciences was trading at Rs2,166.10 per piece, up by 10.15% from its previous closing of Rs1,966.50 on the BSE. The scrip opened at Rs1,930 and touched intraday high and low of Rs2,198.50 and Rs1,930 respectively.

For feedback and suggestions, write to us at [e-mail]